Xcout Intel
Centauri Therapeutics competitors & alternatives
The 12 closest competitors and alternatives to Centauri Therapeutics among biotechnology companies — ranked by similarity to what Centauri Therapeutics actually does, not by market-cap band.
Subscribe to see Centauri Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Centauri Therapeutics
Centauri Therapeutics Limited is a privately held immunotherapy company with its primary headquarters located in London, United Kingdom.
Centauri Therapeutics at a glance
Centauri Therapeutics is a biotechnology company headquartered in United Kingdom, founded in 2014. Its most recent funding round, Series A, raised $32.9M in February 2026. Xcout tracks 11 named people at Centauri Therapeutics, including Jennifer Schneider (Chief Executive Officer , Director).
Centauri Therapeutics leadership
- Jennifer SchneiderChief Executive Officer , Director
- Samantha MacroChief Financial Officer
- Debra BarkerChief Medical Officer
- Helen BrightChief Scientific Officer
- Mike WestbyChief Scientific Officer
- David RoblinChair of the Board of Directors
5 more named people on record for Centauri Therapeutics, with roles, board committees and tenure — see the full roster →
Centauri Therapeutics funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $32.9M | 5 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Centauri Therapeutics competitors
Ranked by semantic similarity — how close each company is to Centauri Therapeutics by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Life Sciences
Cytospire Therapeutics Limited is a biotechnology research company based in London, United Kingdom. The company is focused on developing a portfolio of next-generation immune cell engagers to improve patients' lives.
Similar biotechnology company
Alchemab Therapeutics Ltd is a biotechnology company headquartered in London, England, focused on pioneering patient-centric antibody discovery and development.
Life Sciences
Leucid Bio is a privately held clinical-stage biotechnology company headquartered in London, United Kingdom, with research operations based at Guy's Hospital. The firm translates CAR-T cell research originating from King's College London into novel cancer immunotherapies.
Similar biotechnology company
Pheon Therapeutics is a biotechnology research company headquartered in London, England, that specializes in developing next-generation antibody-drug conjugates for hard-to-treat cancers.
Similar biotechnology company
Valink Therapeutics Inc. is a biotechnology research company headquartered in Cambridge, Massachusetts, with a research and development subsidiary located in London, United Kingdom.
Similar biotechnology company
Century Therapeutics is an innovative biotechnology company headquartered in Philadelphia, Pennsylvania. Its mission is to develop allogeneic, iPSC-derived NK and T cell therapies that are designed to be more effective, tolerable, and accessible.
Similar biotechnology company
Grey Wolf Therapeutics is a biotechnology company headquartered in the UK focused on delivering a new class of treatments to improve the lives of people with cancers and autoimmune disorders.
Similar biotechnology company
Laverock Therapeutics is a biotechnology research company headquartered in London, England, that develops programmable advanced therapies.
Biotech
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.
Similar biotechnology company
Mestag Therapeutics is an immunotherapy company focusing on fibroblast-immune biology to address critical unmet needs in inflammatory diseases and oncology. The company operates across hubs including Cambridge, United Kingdom, and Ghent, Belgium.
Similar biotechnology company
Apollo Therapeutics is a biopharmaceutical company with headquarters located in Cambridge, United Kingdom, alongside offices in Boston, Massachusetts. The company advances breakthrough science to build a portfolio of innovative therapeutics.
Similar biotechnology company
Neotx Holdings Ltd. is a biopharmaceutical company that develops cancer therapeutics and immunotherapies. It conducts clinical trials and researches proprietary technologies aimed at advancing cancer treatment.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Centauri Therapeutics and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Centauri Therapeuticsand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →